Umoja wa Ulaya - Kilatvia - EMA (European Medicines Agency)

ucb pharma sa - brivaracetāms - epilepsija - antiepileptics, - briviact ir norādīts kā adjunctive terapiju daļēju sākums lēkmju ar vai bez sekundāras vispārināšanas pieaugušo un pusaudžu pacientiem no 16 gadu vecuma ar epilepsiju.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - flogaveiki - antiepileptics, - briviact er ætlað sem viðbótarmeðferð við meðhöndlun á flogaveiki með eða án aukakvilla hjá fullorðnum og unglingum frá 16 ára aldri með flogaveiki.

Lativia - Kilatvia - Zāļu valsts aģentūra

teva pharma b.v., netherlands - karbamazepīns - tablete - 200 mg

Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilepsi - antiepileptika, - briviact er indiceret som supplerende terapi til behandling af partielle anfald med eller uden sekundær generalisering hos voksne og unge patienter fra 16 år med epilepsi.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilepsi - antiepileptika, - briviact indikeras som tilläggsbehandling vid behandling av partiella anfall med eller utan sekundär generalisering hos vuxna och ungdomar från 16 år med epilepsi.

Lativia - Kilatvia - Zāļu valsts aģentūra

novartis baltics, sia, latvia - karbamazepīns - modificētās darbības apvalkotā tablete - 200 mg

Lativia - Kilatvia - Zāļu valsts aģentūra

teva pharma b.v., netherlands - karbamazepīns - ilgstošās darbības tablete - 400 mg

Lativia - Kilatvia - Zāļu valsts aģentūra

novartis baltics, sia, latvia - karbamazepīns - modificētās darbības apvalkotā tablete - 400 mg

Marekani - Kiingereza - NLM (National Library of Medicine)

ucb, inc. - brivaracetam (unii: u863jgg2ia) (brivaracetam - unii:u863jgg2ia) - brivaracetam 10 mg - briviact is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. hypersensitivity to brivaracetam or any of the inactive ingredients in briviact (bronchospasm and angioedema have occurred) [see warnings and precautions (5.4)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as briviact, during pregnancy. encourage patients who are taking briviact during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary available data from the north american antiepileptic drug (naaed) pregnancy registry, a prospective cohort study, case reports, and a case series are insufficient to identify a risk of major birth defects, miscarriage or other maternal or fetal outcomes associated with briviact use during pregnancy. in animal studies, briva

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 75 mg - tablet, film coated - excipient ingredients: lactose monohydrate; betadex; croscarmellose sodium; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol; ferrosoferric oxide - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy